On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

State Farm has the cheapest non-owner car insurance, at $213 per year. Non-owner auto insurance is for drivers who don't own a car but still want coverage while they are renting vehicles or driving ...

This copy is for your personal, noncommercial use only. 2 weeks on the list by Maggie Haberman and Jonathan Swan Simon & Schuster Audio Two White House correspondents for The New York Times delve into ...

Rajeev Dhir is a writer with 10+ years of experience as a journalist with a background in broadcast, print, and digital newsrooms. Thomas J. Brock is a CFA and CPA with more than 20 years of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Access detailed historical stock prices, including daily closing prices, for RXRX. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...

Long non-coding RNAs (lncRNA) are a type of non-coding RNAs (ncRNAs) that exceed 200 nucleotides in length. lncRNAs are a relatively abundant component of the mammalian transcriptome and have been ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...